Tag Archives: Biotech

Recent Judicial Rulemaking Leaves Life Science Patents Hanging In The Balance

Editor’s note: This post is part of a series stemming from the Third Annual Health Law Year in P/Review event held at Harvard Law School on Friday, January 30, 2015. The conference brought together leading experts to review major developments in health law over the previous year, and preview...

April 2, 2015

Health Affairs Event Reminder: Biomedical Innovation

Biomedical innovation lengthens and enriches our lives through breakthroughs in medications and care, but it is has also been the leading source of health care cost growth over the past few decades. The February 2015 thematic issue of Health Affairs examines the topic from many...

February 3, 2015

Health Affairs’ February Issue: Biomedical Innovation

The February issue of Health Affairs includes a number of studies examining issues pertaining to biomedical innovation. Some of the subjects covered: how declining economic returns for new drugs may affect future investments, the changing landscape of Medicare coverage determinations for...

February 2, 2015

Health Affairs Briefing: Biomedical Innovation

Biomedical innovation lengthens and enriches our lives through breakthroughs in medications and care, but it is has also been the leading source of health care cost growth over the past few decades. The upcoming February 2015 thematic issue of Health Affairs examines the topic from many...

January 20, 2015

Sovaldi, Harvoni, And Why It’s Different This Time

With the Food and Drug Administration (FDA)’s approval of Harvoni, the successor to Gilead Science’s Sovaldi, the alarm bells have officially rung on breakthrough hepatitis C treatments. One can’t open a newspaper or scan a Twitter feed without stumbling on at least one reference to either of...

November 21, 2014

The Latest Health Wonk Review

In this week's "turkey edition" of the Health Wonk Review, David Harlow of HealthBlawg provides a veritable smorgasbord of health policy posts, including a Health Affairs Blog essay by Jordan Paradise on biosimilars and patent disclosures.

November 21, 2014

Battle Lines Drawn Over Biosimilar Application And Patent Disclosure Process

The Biosimilars Price Competition and Innovation Act of 2009 (BPCIA) introduced a long-awaited, and highly-supported, abbreviated route to market for “biosimilar” and “interchangeable” biologic products. The goal was to create incentives for development and reduce health care costs in the same...

November 17, 2014

Adult Conversation On High-Priced Drugs? Don’t Hold Your Breath (But Hang In There) …

The benevolent identity of the health care enterprise tends to moderate disagreements and keep them under a big tent of shared goals. In the case of very high prices for powerful new drugs, however, the commons gets stretched painfully thin. Drug companies which see themselves as pioneers are...

October 27, 2014

Health Affairs October Issue: Specialty Drugs — Cost, Impact, And Value

The October issue of Health Affairs, released today, includes a number of studies looking at the high costs associated with today’s increasingly prevalent specialty drugs. Other subjects covered in the issue: an assessment of whether some hospitals may be taking advantage of the 340B drug...

October 6, 2014

Reminder: Health Affairs Briefing: Specialty Pharmaceuticals

We live in an era of specialty pharmaceuticals -- drugs typically used to treat chronic, serious or life threatening conditions such as cancer, rheumatoid arthritis, growth hormone deficiency, and multiple sclerosis.  Their cost is often much higher than traditional drugs, and they are set to...

October 3, 2014